NCT03519412
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03519412 |
| Title | Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status (ARETHUSA) |
| Acronym | ARETHUSA |
| Recruitment | Unknown status |
| Gender | both |
| Phase | Phase II |
| Variant Requirements | Yes |
| Sponsors | IFOM ETS - The AIRC Institute of Molecular Oncology |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | ITA |
CKB BOOST